Evidence map›Paper›PMID 33981016›Full record

ArticleBritish journal of cancer2021

Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.

Xing Xu, Yao Wang, Nicole S Bryce, Katrina Tang, Nicola S Meagher, Eun Young Kang, Linda E Kelemen, Martin Köbel, Susan J Ramus, Michael Friedlander and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Alterations of actin in aging.Journal of cell science · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Research Advances in the Role of the Tropomyosin Family in Cancer.International journal of molecular sciences · 2023
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Xing XuSchool of Medical Sciences, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-1323-7141
Yao WangSchool of Medical Sciences, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Nicole S BryceSchool of Medical Sciences, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Katrina TangDepartment of Anatomical Pathology, Prince of Wales Hospital, Sydney, NSW, Australia.
Nicola S MeagherSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Eun Young KangDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Linda E KelemenSouth Carolina Department of Health and Environmental Control, North Charleston, SC, USA.
Martin KöbelDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
Susan J RamusSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Michael FriedlanderPrince of Wales Clinical School UNSW and Department of Medical Oncology, The Prince of Wales Hospital, Sydney, NSW, Australia.
Caroline E FordSchool of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-4438-2309
Edna C HardemanSchool of Medical Sciences, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia.
Peter W GunningSchool of Medical Sciences, Faculty of Medicine, University of NSW Sydney, Sydney, NSW, Australia. p.gunning@unsw.edu.au.
Cancer Institute of New South Wales · AUPrince of Wales Hospital · AUUniversity of Calgary · CASouth Carolina Department of Health and Environmental Control · USThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-microtubule agents are widely used to treat ovarian cancers, but the efficacy is often compromised by drug resistance. We investigated co-targeting the actin/tropomyosin cytoskeleton and microtubules to increase treatment efficacy in ovarian cancers and potentially overcome resistance.

methodsThe presence of tropomyosin-3.1 (Tpm3.1) was examined in clinical specimens from ovarian cancer patients using immunohistochemistry. Combinatorial effects of an anti-Tpm3.1 compound, ATM-3507, with vinorelbine and paclitaxel were evaluated in ovarian cancer cells via MTS and apoptosis assays. The mechanisms of action were established using live- and fixed-cell imaging and protein analysis.

resultsTpm3.1 is overexpressed in 97% of tumour tissues (558 of 577) representing all histotypes of epithelial ovarian cancer. ATM-3507 displayed synergy with both anti-microtubule agents to reduce cell viability. Only vinorelbine synergised with ATM-3507 in causing apoptosis. ATM-3507 significantly prolonged vinorelbine-induced mitotic arrest with elevated activity of the spindle assembly checkpoint and mitotic cell death; however, ATM-3507 showed minor impact on paclitaxel-induced mitotic defects. Both combinations substantially increased post-mitotic G1 arrest with cyclin D1 and E1 downregulation and an increase of p21

conclusionCombined targeting of Tpm3.1/actin and microtubules is a promising treatment strategy for ovarian cancer that should be further tested in clinical settings.

Indexed as

Up-RegulationAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationCell SurvivalChloridesDrug SynergismFemaleHumansMiddle AgedOvarian NeoplasmsPaclitaxelChloridesPaclitaxelTPM3 protein, humanTropomyosinVinorelbine

Identifiers

PMID33981016
PMCPMC8292367
OpenAlexW3160120934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.